BlueStar

By Dave Muoio April 18, 2018
Novo Nordisk and San Francisco-based Sempre Health have announced their collaboration on a pilot program that will offer diabetes medications through the latter company’s monetary incentive and SMS-driven prescription refill platform. The partnership is hoping to engage 10,000 diabetes patients on Sempre’s platform within 2018. “Looking at some of the metrics that Sempre has been able to provide...
By Dave Muoio March 6, 2018
Samsung Health users will now have access to a new consumer-grade version of WellDoc’s digital diabetes management platform, the two companies announced this morning. The Diabetes Wellness Program is a 12-week wellness program designed to help Type 2 diabetes patients improve unhealthy behaviors and better manage their condition. The program is available through the Samsung Health version 5.14 or...
By Laura Lovett January 17, 2018
WellDoc’s digital diabetes management therapeutic BlueStar will now be available on the Solera network as a diabetes management option. Phoenix, Arizona-based Solera Health, a platform which offers a marketplace for chronic disease management programs, and digital therapeutic maker WellDoc announced the partnership today, and said that the partnership aligns both companies' goals to improve the...
By Heather Mack April 19, 2017
Baltimore, Maryland-based WellDoc, which makes a digital platform for chronic disease management, is teaming up with consumer electronics giant Samsung to offer an integrated tool for people living with diabetes. BlueStarC will be available directly to consumers under Samsung’s newly launched mobile health app Samsung Health (formerly known as S Health). The diabetes management app is the third...
By Heather Mack March 31, 2017
In the first quarter of 2017, we tracked seven digital health-related FDA clearances. While the list isn’t long, it’s varied and relatively novel – from app and device integrations for diabetes treatment to a vest that maps cardiac rhythms. The beginning of this year also rang in some big changes, as the Trump Administration took root and nominated Dr. Scott Gottlieb as FDA deputy commissioner....
By Heather Mack January 19, 2017
The US Food and Drug Administration has given the green light for a non-prescription version of BlueStar, WellDoc’s mobile diabetes management platform. Through this 510(k) class II clearance, WellDoc will now offer BlueStar and BlueStar Rx, allowing the company to offer the product through more channels. Both versions analyze diabetes data entered by the patient, comparing past data trends to...
By Jonah Comstock January 4, 2017
WellDoc announced today a partnership with the American Association of Diabetes Educators (AADE), a professional membership organization of over 14,000 diabetes educators. WellDoc will incorporate educational content from AADE into its FDA-cleared, reimburseable BlueStar system for diabetes management.  "We were able to build a curriculum that will be able to be delivered in a contextually guided...
By Heather Mack December 19, 2016
The FDA has cleared the wireless integration of one of Johnson and Johnson subsidiary LifeScan’s blood glucose monitoring systems and WellDoc’s digital diabetes management platform for people with type 2 diabetes. The two companies originally teamed up in March of this year. The integrated system consists of OneTouch Verio Flex, LifeScan’s Bluetooth smart blood glucose monitoring system and...
By Jonah Comstock September 14, 2016
The partnership announced in March between Johnson & Johnson subsidiary LifeScan and diabetes management company WellDoc has entered a new stage with a commercial partnership agreement, the companies announced yesterday.  "We’ve made considerable progress in our important relationship with LifeScan, Inc., which began earlier this year via a development agreement and a Johnson & Johnson...
By Aditi Pai March 1, 2016
Baltimore, Maryland-based WellDoc has announced a collaboration with LifeScan, a Johnson and Johnson company that makes blood glucose meters. WellDoc also raised an additional $7.5 million from Johnson & Johnson Innovation and other investors, bringing the company’s total funding in its most recent round to $29.5 million.  Existing investors include Samsung Ventures, Merck Global Health...

Editor's Pick